Benzinga | Jul 28, 2021 04:05PM EDT

Biomarin Pharmaceutical Q2 EPS $0.07 Beats $(0.11) Estimate, Sales $501.70M Beat $448.79M Estimate

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.11) by 163.64 percent. This is a 143.75 percent increase over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $501.70 million which beat the analyst consensus estimate of $448.79 million by 11.79 percent. This is a 16.81 percent increase over sales of $429.49 million the same period last year.